Synthesis and function of gut-associated lymphoid-tissue-resident *Alcaligenes faecalis* lipooligosaccharide partial structures

(¹Graduate School of Science, Osaka University, ²PRC, Graduate School of Science, Osaka University, ³National Institutes of Biomedical Innovation, Health, and Nutrition) OTomoya Uto¹, Atsushi Shimoyama^{1,2}, Haruki Yamaura¹, Koji Hosomi³, Jun Kunisawa³, Koichi Fukase^{1,2} **Keywords**: symbiotic bacteria; lipid A; Kdo; lipooligosaccharide; innate immunity

Alcaligenes faecalis is a Gram-negative bacterium inhabiting the gut-associated lymphoid-tissue, such as Peyer's patches. We previously reported that lipooligosaccharide (LOS) extracted from *A. faecalis* showed efficient antibody production effect without triggering any harmful responses¹, thus *A. faecalis* LOS and its active center lipid A are expected to be applied as a vaccine adjuvant.

We recently characterized the chemical structure of *A. faecalis* LOS and synthesized its lipid A moiety **1-3** via disaccharide intermediate 6^2 . *A. faecalis* LOS and synthesized lipid A **1** showed the TLR4-dependent immunostimulating activities, while synthesized *A. faecalis* lipid A **2**, **3**, which were the main components in *A. faecalis* LOS, worked as TLR4 antagonists. Thus, there was a functional divergence between the main component lipid As and LOS. On the other hand, we previously found that the Kdo linking lipid A and core oligosaccharide affect the immune function of lipid A³.

In this study, to investigate how Kdo impacts the immune function of *A. faecalis* lipid A, we synthesized *A. faecalis* Kdo-lipid A **4**, **5**. After glycosylation of **7** with Kdo donor **8**⁴ whose sugar backbone was fixed in a boat-like conformation to enhance the α -selectivity of glycosylation, selective removal of protective groups and sequential introduction of fatty acids afforded *A. faecalis* Kdo-lipid A **4**. In a similar strategy to the synthesis of **4**, we also synthesized **5** from **7** and Kdo donor **9**. Bioassay using HEK-BlueTM hTLR4 indicated that Kdo-lipid A **4** showed slightly stronger immunostimulating activity than lipid A **1**.



(1) Mucosal Immunology **2018**, 11, 693. (2) Angew. Chem. Int. Ed. **2021**, 60, 10023. (3) Angew. Chem. Int. Ed. Engl. **2001**, 40, 1475. (4) SYNLETT **2011**, 16, 2359.